Publications by authors named "Geetanjali Uppal"
NPJ Vaccines
September 2018
Article Synopsis
- Reticulocyte invasion by Plasmodium vivax relies on the Duffy-binding protein (PvDBP) interacting with the host Duffy antigen receptor for chemokines (DARC), and targeting this interaction could help prevent malaria growth.
- A Phase I trial with 36 healthy male participants assessed the safety and immune response of the PvDBPII vaccine combined with an adjuvant (GLA-SE), revealing no serious adverse effects and good tolerance.
- Results showed that all doses of the vaccine produced antibodies that effectively inhibited interactions between PvDBP and DARC, with the highest dose demonstrating the strongest and most enduring antibody response, suggesting potential for future malaria prevention efforts.
